COVID-19 in patients with autoimmune diseases : characteristics and outcomes in a multinational network of cohorts across three countries
Tan, Eng Hooi (University of Oxford. Centre for Statistics in Medicine)
Sena, Anthony G. (Erasmus University Medical Center)
Prats-Uribe, Albert (University of Oxford. Centre for Statistics in Medicine)
You, Seng Chan (Suwon)
Ahmed, Waheed-Ul-Rahman (University of Exeter)
Kostka, Kristin (Real World Solutions)
Reich, Christian (Real World Solutions)
Duvall, Scott L. (Salt Lake City)
Lynch, Kristine E. (Salt Lake City)
Matheny, Michael E. (Vanderbilt University Medical Center)
Duarte-Salles, Talita 1985- (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Bertolin, Sergio Fernandez (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Hripcsak, George (New York-Presbyterian Hospital)
Natarajan, Karthik (New York-Presbyterian Hospital)
Falconer, Thomas (Columbia University. Department of Biomedical Informatics)
Spotnitz, Matthew (Columbia University)
Ostropolets, Anna (Columbia University)
Blacketer, Clair (Erasmus University Medical Center)
Alshammari, Thamir (King Saud Univeristy. Medication Safety Research Chair)
Alghoul, Heba (Islamic University of Gaza)
Alser, Osaid (Harvard Medical School)
Lane, Jennifer C. E. (University of Oxford. Centre for Statistics in Medicine)
Dawoud, Dalia (Cairo University)
Shah, Karishma (University of Oxford. Botnar Research Centre)
Yang, Yue (DHC Technologies Co)
Zhang, Lin (The University of Melbourne)
Areia, Carlos (University of Oxford)
Golozar, Asieh (Johns Hopkins Bloomberg School of Public Health (Baltimore, Estats Units d'Amèrica). Department of Epidemiology)
Recalde, Martina (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Casajust, Paula (Real-World Evidence)
Jonnagaddala, Jitendra (UNSW Sydney)
Subbian, Vignesh (The University of Arizona Tucson)
Vizcaya, David (Bayer Pharmaceuticals)
Lai, Lana Y H. (University of Manchester)
Nyberg, Fredrik (University of Gothenburg. Institute of Medicine)
Morales, Daniel R. (University of Dundee)
Posada, Jose D. (Stanford University. Stanford Center for Biomedical Informatics Research)
Shah, Nigam H. (Stanford University. Stanford Center for Biomedical Informatics Research)
Gong, Mengchun (Southern Medical University. Health Management Institute)
Vivekanantham, Arani (University of Oxford. Botnar Research Centre)
Abend, Aaron (Autoimmune Registry Inc)
Minty, Evan P. (University of Calgary. O'Brien School for Public Health)
Suchard, Marc (University of California)
Rijnbeek, Peter (Erasmus University Medical Center)
Ryan, Patrick B. (Columbia University)
Prieto-Alhambra, Daniel (University of Oxford. Centre for Statistics in Medicine)
Universitat Autònoma de Barcelona [...] Mostra tots els 47 autors

Data:	2021
Resum:	Patients with autoimmune diseases were advised to shield to avoid COVID-19, but information on their prognosis is lacking. We characterised 30-day outcomes and mortality after hospitalisation with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza. A multinational network cohort study was conducted using electronic health records data from Columbia University Irving Medical Center (CUIMC) (United States [US]), Optum [US], Department of Veterans Affairs (VA) (US), Information System for Research in Primary Care-Hospitalisation Linked Data (SIDIAP-H) (Spain), and claims data from IQVIA Open Claims (US) and Health Insurance and Review Assessment (HIRA) (South Korea). All patients with prevalent autoimmune diseases, diagnosed and/or hospitalised between January and June 2020 with COVID-19, and similar patients hospitalised with influenza in 2017-2018 were included. Outcomes were death and complications within 30 days of hospitalisation. We studied 133 589 patients diagnosed and 48 418 hospitalised with COVID-19 with prevalent autoimmune diseases. Most patients were female, aged ≥50 years with previous comorbidities. The prevalence of hypertension (45. 5-93. 2%), chronic kidney disease (14. 0-52. 7%) and heart disease (29. 0-83. 8%) was higher in hospitalised vs diagnosed patients with COVID-19. Compared with 70 660 hospitalised with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2. 2% to 4. 3% vs 6. 3% to 24. 6%). Compared with influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	COVID-19 ; Autoimmune condition ; Mortality ; Hospitalisation ; Open science ; Observational Health Data Sciences and Informatics (OHDSI) ; Observational Medical Outcomes Partnership (OMOP)
Publicat a:	Rheumatology, march 2021, ISSN 1462-0332

DOI: 10.1093/rheumatology/keab250
PMID: 33725121

28 p, 649.1 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats